Cite
HARVARD Citation
Kumar, A. et al. (2020). Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease. Crohn's & colitis 360. 2 (4), p. . [Online].